A meta-analysis of seven RCTs demonstrated that CoQ10 supplementation to patients with CKD significantly reduced total cholesterol (TC) (SMD = −0.58; CI, −0.94, −0.21; p = 0.002), LDL-C (SMD = −0.47; 95% CI, −0.78, −0.17; p = 0.003), malondialdehyde (MDA) (SMD = −3.0; 95% CI, −5.10, −0.90; p = 0.005), and creatinine levels (SMD = −1.65; 95% CI, −2.75, −0.54; p = 0.003) yet did not affect fasting glucose, insulin, HOMA-IR, and C reactive protein (CRP) concentrations [143]. The gene discussed is INS; the disease is chronic kidney disease.